Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: a prospective, observational single-center study
Creators: name: Kühn, Dennis
name: Metz, Carlos
name: Seiler, Frederik
name: Wehrfritz, Holger
name: Roth, Sophie
name: Alqudrah, Mohammad
name: Becker, André
name: Bracht, Hendrik
name: Wagenpfeil, Stefan
name: Hoffmann, Mathias
name: Bals, Robert
name: Hübner, Ulrich
name: Geisel, Jürgen
name: Lepper, Philipp M.
name: Becker, Sören L.
Publisher: name: Universität Ulm
Year: 2020
Subjects: subject: Antibiotics
subject: Bacteremia
subject: Diagnosis
subject: Infection
subject: Multiresistant bacteria
subject: Sepsis
subject: Therapeutic drug monitoring
subject: SEVERE SEPSIS
subject: ANTIMICROBIAL THERAPY
subject: ADULT PATIENTS
subject: SEPTIC SHOCK
subject: PHARMACOKINETICS
subject: DETERMINANT
subject: PNEUMONIA
subject: DDC 610 / Medicine &amp; health

description: Abstract Background Effective antimicrobial treatment is key to reduce mortality associated with bacterial sepsis in patients on intensive care units (ICUs). Dose adjustments are often necessary to account for pathophysiological changes or renal replacement therapy. Extracorporeal membrane oxygenation (ECMO) is increasingly being used for the treatment of respiratory and/or cardiac failure. However, it remains unclear whether dose adjustments are necessary to avoid subtherapeutic drug levels in septic patients on ECMO support. Here, we aimed to evaluate and comparatively assess serum concentrations of continuously applied antibiotics in intensive care patients being treated with and without ECMO. Methods Between October 2018 and December 2019, we prospectively enrolled patients on a pneumological ICU in southwest Germany who received antibiotic treatment with piperacillin/tazobactam, ceftazidime, meropenem, or linezolid. All antibiotics were applied using continuous infusion, and therapeutic drug monitoring of serum concentrations (expressed as mg/L) was carried out using high-performance liquid chromatography. Target concentrations were defined as fourfold above the minimal inhibitory concentration (MIC) of susceptible bacterial isolates, according to EUCAST breakpoints. Results The final cohort comprised 105 ICU patients, of whom 30 were treated with ECMO. ECMO patients were significantly younger (mean age: 47.7 vs. 61.2 years; p &lt; 0.001), required renal replacement therapy more frequently (53.3% vs. 32.0%; p = 0.048) and had an elevated ICU mortality (60.0% vs. 22.7%; p &lt; 0.001). Data on antibiotic serum concentrations derived from 112 measurements among ECMO and 186 measurements from non-ECMO patients showed significantly lower median serum concentrations for piperacillin (32.3 vs. 52.9; p = 0.029) and standard-dose meropenem (15.0 vs. 17.8; p = 0.020) in the ECMO group. We found high rates of insufficient antibiotic serum concentrations below the pre-specified MIC target among ECMO patients (piperacillin: 48% vs. 13% in non-ECMO; linezolid: 35% vs. 15% in non-ECMO), whereas no such difference was observed for ceftazidime and meropenem. Conclusions ECMO treatment was associated with significantly reduced serum concentrations of specific antibiotics. Future studies are needed to assess the pharmacokinetic characteristics of antibiotics in ICU patients on ECMO support.